Islets of Hope
|Volume 2, Issue 1: January 2006|
Product Watch: Frio Products Leave Consumers out in the Cold
Editorial: The Great Label Debate: I'm Not Diabetic, I just Have Diabetes
Clinical Trial Update: Arkansas
Lily Cautions that Cymbalta May Increase Risk for Liver Damage
Two New Possibiliites in Stem Cell Research
Warning Issues About Abbott Glucose Meters
Inhaled Insulin Approved by FDA Approval
Stem Cell Institute Opens in Mission Bay, CA
Islets of News Editorial Feature
The Great Label Debate: Are you a diabetic? Or do you just have diabetes?
This book combines a compre- hensive medical approach toward intensive diabetes management and pump therapy with a patient-centered appreciation of the real-life challenges and frustrations.
Sharper Image's CarbTracker Scale This scale is the "weigh" to go for counting carbs and other food nutrients.
Lilly Cautions that Cymbalta may increase risk for liver damage: October 18, 2005. ST. LOUIS (MD Consult) - "On October 17, 2005, Eli Lilly and the US Food and Drug Administration (FDA) notified health care professionals of a revision to the Precautions/Hepatotoxicity section of the prescribing information for Cymbalta (duloxetine hydrochloride), indicated for treatment of major depressive disorder and diabetic peripheral neuropathic pain..."
Diabetes Drugs Approved in 2005
Increlex (mecasermin), a drug from Tercicia was approved fby the FDA in August 2005 for the treatment of growth failure in pediatric patients. Increlex contains recombinant-DNA- engineered human insulin-like growth factor-1 (rhIGF-1). It is designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normal statural growth.
ActoPlus Met - "Takeda Pharm- aceutical Co. has obtained U.S. FDA Administration approval for a new combination of insulin sensitizing drugs, Actoplus Met is a combination of Actos and Metformin." Associated Press, August 30, 2005.
Byettaa (exenatide) - Derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, mimicks the function of GLP-1, the drug helps more strongly activate this pathway to improve glycemic control and is indicated for type 2 treatment.
Symlin (pramlintide) - A synthetic form of the hormone amylin normally produced by the beta cells along with insulin. Amylin, insulin, and a third hormone called glucagon all work together to maintain normal glucose levels. Studies show a modest improvement in A1C levels for individuals adding pramlintide to their diabetes care routine.
Diabetes Drugs May
"Toronto - Two drugs used to treat Type 2 diabetes have been found to cause or worsen a serious vision impairment known as macular edema, Health Canada warned Wednesday.
"The advisory was released after GlaxoSmithKline Inc., the manufacturer of Avandia and Avandamet, informed Health Canada of reports that some diabetics on the drugs had developed the eye condition or had a pre-existing case worsen." Read Full Article
Johnson & Johnson to Acquire Animas Corp.
NEW YORK (AP) — Health products maker Johnson & Johnson (JNJ) said Friday that it has agreed to acquire Animas (PUMP), an insulin delivery company, for about $518 million to capitalize on the growing demand for diabetes treatment.
The acquisition will give Johnson & Johnson immediate entry in the fast-growing insulin delivery pump market, the company said.
J&J, based in New Brunswick, N.J., said it would pay $24.50 for each Animas share, a 35% premium to Animas' Thursday closing stock price on the Nasdaq.
Chicago – A new Illinois law effective January 1, 2006, ensures that consumers can comparison shop to find the lowest price for their prescription medications. Based on that law, Attorney General Lisa Madigan today urged Illinoisans to take advantage of the new law to help lower skyrocketing monthly prescription costs.
12/29/05; Read Press Release
Lipid files FDA Application for Cholesterol Filter
Lipid Sciences Inc. said Thursday it applied for Food and Drug Administration approval to test a device that removes cholesterol from a patient's blood.
Pleasanton-based Lipid (NASDAQ: LIPD) wants to run a clinical trial of the device, called the Plasma Delipidation System-2, which treats human blood plasma to remove HDL cholesterol after that blood has been pumped out of the patient. The treated blood is then returned to the patient's body.
If approved, the trial will be run at the Washington Hospital Center in Washington, D.C. and will enroll 30 male and female patients between ages 18 and 75 who are suffering from coronary heart disease.
Lipid hopes to begin the trial in the first quarter of 2006.
Clinical Trial Update
Studies Recruiting Patients
Page Updated 12/09/2005